Harnessing the quinoline core for targeted cancer therapy.

Authors

Cong-Jun Liu, Wei-Wen Huang, Jun-Jie Wang, Wen-Shuo Jiang, Xin-Yue Zhang, Xin Chen, Ya Gao, Xing-Jie Dai

Published in

Future medicinal chemistry. Pages 1-20. Aug 13, 2026. Epub Aug 13, 2026.

Abstract

The quinoline nucleus is a privileged scaffold valued for its structural plasticity and synthetic accessibility. This review systematically summarizes advances in quinoline derivatives for targeted cancer therapy from 2017 to 2026, organized by major molecular target families - including kinases, metabolic enzymes, epigenetic regulators, drug transporters, and others - with emphasis on rational design, key structure-activity relationships (SARs), and antitumor efficacy. Despite progress, challenges such as isoform selectivity, suboptimal pharmacokinetics, and drug resistance persist; future efforts should focus on dual-targeting and prodrug strategies to overcome these limitations. This review aims to provide medicinal chemistry insights for the design of next-generation quinoline-based anticancer agents with improved selectivity, pharmacokinetic properties, and ability to overcome drug resistance.

PMID:
42593423
Bibliographic data and abstract were imported from PubMed on 13 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.